DE60023141T2 - Selektive npy (y5) antagonisten - Google Patents

Selektive npy (y5) antagonisten Download PDF

Info

Publication number
DE60023141T2
DE60023141T2 DE60023141T DE60023141T DE60023141T2 DE 60023141 T2 DE60023141 T2 DE 60023141T2 DE 60023141 T DE60023141 T DE 60023141T DE 60023141 T DE60023141 T DE 60023141T DE 60023141 T2 DE60023141 T2 DE 60023141T2
Authority
DE
Germany
Prior art keywords
compound
pharmaceutical composition
provides
pharmaceutically acceptable
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60023141T
Other languages
English (en)
Other versions
DE60023141D1 (de
Inventor
R Marzabadi
C Wong
A Noble
Peter Buhlmayer
Heinrich Rueger
Yasuchika Yamaguchi
Walter Schilling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
H Lundbeck AS
Original Assignee
Novartis AG
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/343,635 external-priority patent/US6225330B1/en
Priority claimed from US09/343,633 external-priority patent/US6214853B1/en
Priority claimed from US09/343,993 external-priority patent/US6222040B1/en
Application filed by Novartis AG, H Lundbeck AS filed Critical Novartis AG
Application granted granted Critical
Publication of DE60023141D1 publication Critical patent/DE60023141D1/de
Publication of DE60023141T2 publication Critical patent/DE60023141T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
DE60023141T 1999-06-30 2000-04-21 Selektive npy (y5) antagonisten Expired - Fee Related DE60023141T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/343,635 US6225330B1 (en) 1999-06-30 1999-06-30 Selective NPY (Y5) antagonists (tricyclics)
US09/343,633 US6214853B1 (en) 1999-06-30 1999-06-30 Selective NPY (Y5) antagonists (bicyclics)
US09/343,993 US6222040B1 (en) 1999-06-30 1999-06-30 Selective NPY (Y5) antagonists (tricyclics)
PCT/US2000/011004 WO2001002379A1 (en) 1999-06-30 2000-04-21 Selective npy (y5) antagonists

Publications (2)

Publication Number Publication Date
DE60023141D1 DE60023141D1 (de) 2006-02-23
DE60023141T2 true DE60023141T2 (de) 2006-06-14

Family

ID=27407570

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023141T Expired - Fee Related DE60023141T2 (de) 1999-06-30 2000-04-21 Selektive npy (y5) antagonisten

Country Status (9)

Country Link
EP (1) EP1194421B1 (de)
JP (1) JP2003503486A (de)
AT (1) ATE306477T1 (de)
AU (2) AU773892B2 (de)
CA (1) CA2380866A1 (de)
DE (1) DE60023141T2 (de)
DK (1) DK1194421T3 (de)
ES (1) ES2250126T3 (de)
WO (1) WO2001002379A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342344T3 (es) 1999-11-26 2010-07-05 SHIONOGI & CO., LTD. Antagonistas de npy-y5.
AU2001246494A1 (en) * 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
US7485655B2 (en) * 2002-01-16 2009-02-03 University Of Virginia Patent Foundation 2-Aminothiazole allosteric enhancers of A1 adenosine receptors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
EP2305352A1 (de) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-Reduktaseinhibitoren zur Behandlung von Stoffwechsel- und anthropometrischen Störungen
KR101123549B1 (ko) 2004-11-01 2012-04-18 아밀린 파마슈티칼스, 인크. 비만 및 관련 장애의 치료
WO2006104030A1 (ja) * 2005-03-25 2006-10-05 Daiichi Sankyo Company, Limited チアゾール化合物
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
EP1916239A4 (de) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd Pyridolverbindung
EP1922336B1 (de) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybridpolypeptide mit auswählbaren eigenschaften
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
BRPI0618354B8 (pt) 2005-11-10 2021-05-25 Banyu Pharma Co Ltd composto e seu uso, composição farmacêutica, preventivo ou remédio
NZ572381A (en) * 2006-04-28 2011-01-28 Shionogi & Co Amine derivative having npy y5 receptor antagonist activity
AU2007263809B2 (en) 2006-06-29 2013-07-18 F. Hoffmann-La Roche Ag Tetrazole-substituted arylamides
EP2046736B1 (de) * 2006-07-27 2019-06-12 Emisphere Technologies, Inc. Arylsulfanylverbindungen und zusammensetzungen zur wirkstofffreisetzung
EP2083831B1 (de) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Verfahren zur behandlung von fettsäure-synthese-hemmern
EP2072519A4 (de) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd Diarylketiminderivat
KR101165936B1 (ko) 2006-11-09 2012-07-19 에프. 호프만-라 로슈 아게 티아졸 및 옥사졸-치환된 아릴아마이드
EP2145884B1 (de) 2007-04-02 2014-08-06 Msd K.K. Indoledionderivat
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
JP5389810B2 (ja) 2007-10-04 2014-01-15 エフ．ホフマン−ラ ロシュ アーゲー テトラゾール置換アリールアミド誘導体及びその使用
SA08290668B1 (ar) 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
CA2708228C (en) 2007-12-17 2016-06-21 F. Hoffmann-La Roche Ag Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
WO2009077365A1 (en) 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazole-substituted arylamides
SI2234976T1 (sl) 2007-12-17 2013-07-31 F. Hoffmann-La Roche Ag Novi s pirazolom substituirani arilamidi
EP2225213B1 (de) 2007-12-17 2015-04-29 F. Hoffmann-La Roche AG Triazol-substituierte arylamidderivate und ihre verwendung als agonisten des purinergen rezeptors p2x3 und/oder p2x2/3
PE20091309A1 (es) * 2007-12-21 2009-09-30 Astrazeneca Ab Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
EP2272841A1 (de) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamidderivat mit antagonistischer wirkung auf rezeptor des melaninkonzentrierenden hormons
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (de) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidinderivate und verfahren zu deren anwendung
WO2010101247A1 (ja) 2009-03-05 2010-09-10 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するシクロヘキサン誘導体
US8227618B2 (en) 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
CN102438989B (zh) 2009-06-22 2015-05-27 霍夫曼-拉罗奇有限公司 噁唑酮和吡咯烷酮取代的芳基酰胺
WO2010149578A2 (en) 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel biphenyl and phenyl-pyridine amides
CA2761921A1 (en) 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Indole, indazole and benzimidazole arylamides
WO2011096462A1 (ja) * 2010-02-04 2011-08-11 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環化合物
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MA34916B1 (fr) 2011-02-25 2014-02-01 Merck Sharp & Dohme Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
US8916594B2 (en) * 2011-04-27 2014-12-23 Shionogi & Co., Ltd. 5-membered ring heteroaromatic derivatives having NPY Y5 receptor antagonistic activity
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
CA3038185A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (de) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetische heterocyclische verbindungen
EP3558298A4 (de) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetische spirochromanverbindungen
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (de) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl-pyrrolidin- und piperidinorexinrezeptor-agonisten
IL300610A (en) 2020-08-18 2023-04-01 Merck Sharp ַ& Dohme Llc Bicycloheptane pyrrolidine compounds are orexin receptor agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166214A (en) * 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
JPH10152480A (ja) * 1996-09-25 1998-06-09 Takeda Chem Ind Ltd 三環性化合物、その製造法および剤
CA2251580A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
HUP0003934A3 (en) * 1997-07-03 2002-01-28 Pfizer A part of diaryl imidazole derivatives, pharmaceutical composit
AU775166B2 (en) * 1999-04-22 2004-07-22 H. Lundbeck A/S Selective NPY (Y5) antagonists
PL356485A1 (en) * 1999-12-16 2004-06-28 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists
AU2001246494A1 (en) * 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists

Also Published As

Publication number Publication date
AU4369700A (en) 2001-01-22
AU773892B2 (en) 2004-06-10
EP1194421A1 (de) 2002-04-10
EP1194421B1 (de) 2005-10-12
DK1194421T3 (da) 2006-02-13
EP1194421A4 (de) 2002-09-11
JP2003503486A (ja) 2003-01-28
CA2380866A1 (en) 2001-01-11
ES2250126T3 (es) 2006-04-16
ATE306477T1 (de) 2005-10-15
AU2004208715A1 (en) 2004-09-30
WO2001002379A1 (en) 2001-01-11
DE60023141D1 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
ATE306477T1 (de) Selektive npy (y5) antagonisten
DE60034783D1 (de) Selektive npy(y5)-antagonisten
SE0100568D0 (sv) Compounds
MXPA02005602A (es) Compuestos de urea que tienen actividad antagonista para el receptor muscarinico.
SE0100567D0 (sv) Compounds
MY133378A (en) Glucocorticoid receptor modulators
ES2299896T3 (es) Derivados de benzazepina como antagonistas h3 de histamina.
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
MXPA02005596A (es) Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
IL160755A0 (en) Urea compounds active as vanilloid receptor antagonists for the treatment of pain
DE60001983D1 (de) Bicyclische und tricyclische heteroaromatische verbindungen
HUP0003750A2 (hu) Gyógyszerkészítmények
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
NO20015413D0 (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
AU2003270199A1 (en) Urea compounds active as vanilloid receptor antagonists for the treatment of pain
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
PT1140031E (pt) Preparacao farmaceutica de libertacao controlada com mesilato de tilidina como substancia activa
DE60215313D1 (de) Indolderivate und deren verwendung als gnrh antagonisten
WO2000048581A3 (en) Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
HUP0203338A2 (hu) Integrin receptor ligandumok
UA77025C2 (en) Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr), a pharmaceutical composition and a method for preparation of compounds
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee